RolloverTreatment With Triumeq for People With ALS Following the Lighthouse II Trial

Inclusion Criteria: * Participants diagnosed with ALS according to the Lighthouse II protocol who completed the Lighthouse II trial. * Participants taking Riluzole must be on a stable dose. * Participants taking taurursodiol supplements (TUDCA) can participate in this trial if the supplement does not contain sodium phenylbutyrate. * Women must not become pregnant (e.g., post-menopausal, surgically sterile, using highly effective birth control methods or not having potentially reproductive sex) for the duration of the study plus five days; and women of childbearing potential must have a negative urine pregnancy test at baseline and be non-lactating. * For participants taking antacids (regularly or as required), participant is willing and able to avoid taking antacids for at least 6 hours before and 2 hours after the Triumeq dose. * Capable of providing informed consent and complying with the trial procedures. Exclusion Criteria: * In the Principal Investigator's opinion, the participant is unlikely to be compliant with the study drug dosing. * People who are HLA-B\*5701 positive. * Presence of HIV antibodies at screening * Presence of Hepatitis C antibodies at screening unless participants have had effective treatment for Hepatitis C * Presence of Hepatitis B core or surface antigen at screening * Known hypersensitivity to Dolutegravir, Abacavir or Lamivudine, or to any of the excipients. * Moderate to severe hepatic impairment, as defined by local clinical guidelines. * Participation in any other investigational drug trial or using another investigational drug within 5 half-lives of that drug. * Use of NIV ≥22 h per day or having a tracheostomy * Clinically significant history of unstable or severe cardiac, oncological, psychiatric, hepatic, or renal disease or other medically significant illness * Taking medication contraindicated with Triumeq: Dofetilide or Fampridine (dalfampridine)